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Introduction
Although pre-treatment resistance to
Rifampicin is not common in most countries at
present, it may become more prevalent because
of the increasing use of Rifampicin containing
regimens for the treatment of tuberculosis1.
Rifampicin is being freely used in recent years
in India for the treatment of tuberculosis and
leprosy by Government institutions under the
respective national programmes for control of
these diseases. And also by general practitioners
as well as voluntary organisations. Patients who
take treatment irregularly because of poor case-
holding or who do not respond to treatment with
Rifampicin containing regimens are likely to have
developed resistance to Rifampicin. In a study in
Gujarat, an alarming increase in acquired
resistance to Rifampicin, from 2.8% in 1983 to
37% in 1986 was reported2. Further treatment
of such patients with Rifampicin   resistant
organisms poses a problem since the currently
available reserve drug regimens are not very
effective in these patients, besides being
expensive and highly toxic. The long-acting
Rifamycin derivatives, such as Rifapentine
(Cyclopentyl Rifamycin, MDL 473) and Rifabutin
(Spiro-piperidyl Rifamycin, ansamycin, LM 427)
are considered superior to Rifampicin by some,
based on in vitro investigations3, 4, 5, 6.. Other
workers have reported the activity of Rifapentine
to be similar to that of Rifampicin7,8.
A study was, therefore, undertaken for a
concurrent comparison of susceptibility to
Rifampicin, Rifapentine and Rifabutin, in vitro, of
south Indian isolates of M. tuberculosis
susceptible as well as resistant to Rifampicin.
Material and Methods
Cultures : M. Tuberculosis isolates from 103
patients (51 strains resistant to Rifampicin and 52
strains susceptible to Rifampicin) were precoded
and tested.
Drug concentrations : Rifampicin, Rifapentine
and Rifabutin were each dissolved in dimethyl
formamide and incorporated in Lowenstein-
Jensen medium to give final pre-inspissation
conc ntrations of 1, 2, 4, 8, 16, 32, 64 and 128 ug/
ml.
Susceptibility testing: A standard bacterial
suspension (4 mg/ml) of each isolate was
inoculated (with a 3 mm internal diameter loop)
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on 2 drug-free slopes and one slope with each
concentration of the drugs. All the slopes were
incubated at 37°C, The order of inoculation of the
3 drug-containing slopes was randomised.
Readings were taken at the end of 4 weeks of
incubation. The Minimal Inhibitory
Concentration (MIC) was determined by using
the 20-colony end point10.
Definition of resistance : A strain was
considered to be resistant to Rifampicin or the
other two derivatives if it yielded a growth of 20
colonies or more on 64 ug/ml.10
Results
Rifampicin susceptibility : Of the 103 isolates
tested, 51 were found to be resistant to
Rifampicin (MIC > 128), confirming the earlier
test results at the time of intake.
 Rifampicin susceptible strains
Activity of Rifapentine: All the 52 Rifampicin
susceptible strains were found susceptible to
Rifapentine also (Table 1). The pattern of MIC
values showed Rifapentine to be more effective.
Thus, out of the 52 susceptible strains, 9 had
identical MICs, 2 had a higher MIC for
Rifapentine by 1 dilution (in the lower 2 and 4
ug/ml Rifapentine concentrations), while 41 had
a lower MIC for Rifapentine. Considering the
MICs of these 41 strains, 26 were lower by 1
dilution, 10 by 2 dilutions, 4 by 3 dilutions and 1
by 4 dilutions. Thus, in 15 out of the 52 strains,
Rif pentine showed at least 4 fold higher
eff ctiveness than Rifampicin. The geometric
mean MIC of the 52 strains was 13.3 ug/ml for
Rifampicin and 6.0 ug/ml for Rifapentine,
showing a 2.2 times higher effectiveness with
Rifapentine (95% confidence interval : 1.8-2.7).
The difference between the mean MTCs, tested
after carrying out a logarithmic transformation,
was found to be highly significant statistically
(P < 0.001).
Activity of Rifabutin : Among the 52
Rifampicin susceptible strains, 2 strains had an
MIC identical with Rifampicin and the remaining
50 showed a lower MIC for Rifabutin. Of the
latter, the MICs of 8 strains were lower by 1
dilution; 1 by 2 dilutions, 12 by 3 dilutions, 16 by 4  
dilu ions and 13 by 5 dilutions (Table 2). Thus, in
42 out of the 52 strains, Rifabutin showed at least
4 fold higher effectiveness than Rifampicin. The
geometric mean MIC of the 52 strains was 1.3
ug/ml with Rifabutin compared to 13.3 ug/ml
with Rifampicin, showing an average of 10.2 fold
higher effectiveness (95% confidence interval :
7.7-13.8). The difference between the mean MICs
was highly significant statistically (P < 0.001).
Rifampicin resistant strains
Activity of Rifapentine: All the 51 Rifampicin
resistant strains were resistant to Rifapentine
also, indicating a cross-resistance between the
two compounds. Of these, 47 had identical MICs,
while 2 strains had an MIC 1 dilution higher with
Rifapentine and the remaining 2 had an MTC 1
Table 1  MICs of Rifampicin and Rifapentine for M. tuberculosis isolates
Rifampicin
MIC (ug/ml) 
< 1 2 4
Rifapentine MIC (ug/ml)
8 16 32 64 128 > 128 Total
< 1 1 1 2
2 2 3 1 6
4 1 1 2
8  6 1 7
16 1 1 9 2 13
32 1 3 9 8 21
64 1 1
128 8 2 10
> 128 2 39 41
Total 3 7 12 19 10 1 10 41 103
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13 6 2 21
1 1
1 4 2 3 10
3 18 19 41
Total 39 11 2 4 1 6 21 19 103
dilution higher with Rifampicin (Table 1). Thus,
among rifampicin resistant strains, Rifapentine
did not show increased effectiveness.
Activity of Rifabutin : With Rifabutin, 11 (22%)
of the51 strains were susceptible. Of the
remaining 40 strains, 22 had an identical MIC
while in 18 the MIC was 1 dilution lower with
Rifabutin (Table 2). The geometric mean MIC of
the 51 strains was 223 ug/ml with Rifampicin
compared to 113 ug/ml with Rifabutin. For the
purpose of calculating the means, the MIC of
>128 was taken as 256. Thus, among Rifampicin
resistant strains, Rifabutin showed a 1.97 fold
higher effectiveness (95% confidence interval :
1.5-2.6). The difference in the mean MICs
attainedhigh statistical significance (P < 0.001).
Discussion
Rifapentineand Rifabutin have been
considered to be more effective than Rifampicin
in Rifampicin susceptible strains based on in vitro
investigations. Arioli et al3 reported Rifapentine
to be 2-10 fold more effective than Rifampicin in
Kirchner’s liquid medium while Dickinson and
Mitchison9 found a 4 fold higher activity in 7H10
agar. However, Yates and Collins8 f u d the two
compounds to have similar activity on LJ
medium. Similar findings were also reported by
Truffot et al7. The differences could possibly be
due to protein binding as it is known that the
Rifamycins bind rapidly to proteins and the
binding capacity is higher for Rifapentine than for
Rifampicin.11 Unpublished findings from this
Centr  showed that MICs of Rifapentine and
Rifampicin were five to six fold lower in 7H11
agar than on LJ medium.
Our investigation has shown Rifabutin to be
more effective than Rifapentine : 41 of 52 (79%)
R fampicin susceptible strains were more
susceptible by three or more dilutions to
Rifabutin         over Rifampicin while the
corr sponding proportion for Rifapentine was
only 10% (5/52). Besides, a small proportion of
strains resistance to Rifampicin in vitro were found
susceptible to Rifabutin: 22% in our study, 36%
of 44 by Woodley and Kilburn6, 11% of 37 by
Hawkins et al5 nd 31% of 35 by Mitchison et al1.
The characteristic of Rifabutin as indicated by
the manufacturers is that concentration of the
drug in tissues is several times higher than in
serum (0.39 ug/ml after 300 mg oral dose), the
serum level being a pproximately 10 times lower
than that with_ e same dose of Rifampicin12. The
serum half-life of Rifabutin is 16 hours13 and
protein binding is only 25% of that for
Rifampicin14.
With increasein Rifampicin acquired
resistance,Rifabutin may be useful for treating
patients with Rifampicin resistant organisms. The
longer half-life of Rifabutin could possibly delay
the emergenceof resistance in patients who are
resistant to the companion drugs and probably
make it particularly suitable for intermittent
administration. This could be validated only after
well-planned controlled clinical trials conducted
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to assess the activity of Rifabutin in Rifampicin
resistant tuberculosis.
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